Phibro Animal Health Corporation

PAHC

CIK 0001069899 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$374M
↑+20.9% +$65Mvs FY2024 (Q4)
Operating Income
$50M
↑+97.1% +$25Mvs FY2024 (Q4)
Net Income
$27M
↑+762.1% +$24Mvs FY2024 (Q4)
Gross Profit
$133M
↑+30.2% +$31Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
64/100
  • Profitability
    28ROIC 10.6% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.76 (above 1.5 = solid)
  • Leverage
    0D/E 2.21 (under 0.5 = conservative)
  • Efficiency
    70Asset Turnover 1.11x (1.0+ = capital-efficient)
  • Growth
    86Revenue YoY +20.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 13.5% · trend +4.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project PAHC's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$17.69
Total enterprise IV
$720M
Diluted shares
0.04B
Terminal PV
$522M (72% of total)
Year-5 FCF
$61M
YearProjected FCFDiscounted PV
+1$45M$41M
+2$49M$40M
+3$53M$40M
+4$57M$39M
+5$61M$38M
Terminal$840M$522M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$46M
investment in PP&E
Dividends paid (TTM)
$19M
cash returned to holders
Stock-based comp (TTM)
$1M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.41B
everything owned
Total liabilities
$1.07B
everything owed
Stockholders' equity
$332M
shareholder claim
Net debt
$569M
LT debt minus cash

Recent performance · 55 quarters

Revenue↑+20.9% +$65M
$374M
Net Income↑+762.1% +$24M
$27M
Free Cash Flow↑+273.9% +$13M
$8M
Operating Margin↑+5.2pts
13.5%

Drill down